Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/30959

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/30959

Title:	Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer
Authors:	Lu, Yin-Che Ou-Yang, Fu Hsieh, Chia-Ming Chang, King-Jen Chen, Dar-Ren Tu, Chi-Wen Wang, Hwei-Chung Hou, Ming-Feng
Contributors:	Ditmanson Med Fdn Chiayi Christian Hosp, Dept 1Hematol Oncol Ditmanson Med Fdn Chiayi Christian Hosp, Dept Surg Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Kaohsiung Med Univ Hosp, Dept Surg Taiwan Adventist Hosp, Breast Ctr Natl Taiwan Univ Hosp, Dept Surg Cheng Ching Gen Hosp, Dept Surg Changhua Christian Hosp, Dept Surg China Med Univ Hosp, Dept Surg Kaohsiung Municipal Hsiaokang Hosp
Keywords:	Breast cancer adjuvant chemotherapy pegylated liposomal doxorubicin older
Date:	2016-03
Issue Date:	2018-01-18 11:38:44 (UTC+8)
Publisher:	Int Inst Anticancer Research
Abstract:	Background: Conventional anthracyclines play an essential role for the treatment of breast cancer and have potent cytotoxic activity, but are associated with severe toxicity. In metastatic breast cancer, pegylated liposomal doxorubicin (PLD) is a formulation with efficacy similar to conventional doxorubicin but with reduced toxicity. This multicenter study evaluated the efficacy and safety of PLD-based adjuvant chemotherapy for women with stage I-III operable breast cancer. Patients and Methods: One hundred and eighty women with stage I-III breast cancer who received PLD-based adjuvant chemotherapy at six different Institutions in Taiwan from February 2002 to March 2008 were included and followed-up until April 2015. Treatment efficacy was determined by disease-free survival (DFS) rate and safety was evaluated by adverse events. Results: The 5- and 10-year DFS rates were 76.3 and 72.6%, respectively. Univariate analysis revealed that tumor size >5 cm (p=0.045; hazard ratio=3.31) and stage III (hazard ratio=3.54; p=0.019) were each associated with shorter DFS. Only stage III (hazard ratio=5.60; p=0.018) retained statistical significance with regard to DFS in the multivariate analysis. Grade 3/4 hematological toxicity was neutropenia (n=13; 7.2%). The women receiving PLD had low-grade 3 or 4 nausea/vomiting, mucositis, and alopecia. Grade 3 hand-foot syndrome occurred in three patients (1.7%). Conclusion: PLD could be considered an effective and safe alternative to conventional anthracyclines in the treatment of stage I-III operable breast cancer.
Relation:	In Vivo, v.30 n.2, pp.158-162
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
30959.pdf		77Kb	Adobe PDF	475	View/Open
index.html		0Kb	HTML	1608	View/Open

Loading...